Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool January 7, 2005 Brian Gorman	Canadian Drug Sales Might End Drug makers may not have to worry about cheap pills flooding into the U.S. from across the border, at least for now, offering a small consolation to investors.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool January 22, 2007 Michael P. Cecil	Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it?
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
Managed Care December 2000	How To Save Money on Prescriptions There are ways for low-income groups to avoid paying top dollar for prescriptions. Here's one way physicians can educate consumers...
The Motley Fool November 22, 2005 Brian Gorman	Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.
The Motley Fool December 13, 2004 Brian Gorman	Which Medications Are Your Best Bets? Consumer Reports' effort to rate drugs offers a marketing lesson to pharmaceutical companies.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
Pharmaceutical Executive January 1, 2006 Bill Shearer	Patient Assistant Programs and Medicare Part D About 2.5 million low-income seniors who participate in prescription access programs are eligible for drug coverage under Medicare Part D - but the programs are out of alignment.
The Motley Fool July 7, 2004 Charly Travers	Pfizer Wants to Be Your Pfriend It seems that the pharmaceutical is limiting its profits in certain markets on its own terms in the hopes that concessions will be sufficient to keep from being handcuffed by Congress.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool June 12, 2006 Brian Gorman	Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note.
Knowledge@Wharton	Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new study comparing average prices for pharmaceuticals in nine countries -- the US, Canada, Chile, France, Germany, Italy, Japan, Mexico and the UK -- shows that average prices are highest in Japan, while prices in other countries are between 6% and 33% lower than prices in the US.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool May 6, 2008 Brian Orelli	Free Drugs Free over-the-counter drugs are a win-win for health insurers and their members.
Managed Care February 2006	For Drugs, the VA Pays Far Less Than Medicare A recent survey indicates that prices for the top 20 drugs used by Medicare enrollees are much higher than prices negotiated by the Department of Veterans Affairs.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
Managed Care March 2002	How Medicare beneficiaries spend money on drugs The Kaiser Family Foundation notes that Medicare beneficiaries account for 14 percent of the U.S. population, but for 43 percent of the nation's spending on prescription drugs. Thirteen percent of beneficiaries had to pay $2,000 or more out of pocket in 2001...
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Managed Care May 2002	Drug Companies Unveil Their Plan For Discount Card In the absence of any congressional action on a pharmacy benefit in Medicare, seven pharmaceutical companies have teamed up to offer a drug discount card that many call a vital first step in shoring up Medicare coverage
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool February 4, 2008 Chuck Saletta	Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
The Motley Fool May 7, 2004 Brian Gorman	CVS Fuels the Drug Debate Thomas Ryan, the CEO of CVS, supports reimporting drugs from Canada before Congress. Drugs from European companies may actually have a greater impact on price.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.